PepGen Shares Data From Low-Dose Cohort Of PGN-EDO51 In Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial For Treatment Of Duchenne Muscular Dystrophy; Says Was Well Tolerated, And All Patients Continued To Long-Term Extension Portion Of Trial. Dosing Of Second Cohort At 10 mg/kg Is Ongoing
Portfolio Pulse from Benzinga Newsdesk
PepGen Inc. (NASDAQ:PEPG) announced positive clinical data from the first dose cohort of PGN-EDO51 in its Phase 2 trial for Duchenne muscular dystrophy. The treatment was well tolerated, and all patients continued to the long-term extension portion of the trial. The company will host a conference call to discuss the data.
July 30, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PepGen Inc. reported positive clinical data from the first dose cohort of PGN-EDO51 in its Phase 2 trial for Duchenne muscular dystrophy. The treatment was well tolerated, and all patients continued to the long-term extension portion of the trial. The company will host a conference call to discuss the data.
The positive clinical data and the continuation of all patients to the long-term extension portion of the trial are likely to boost investor confidence in PepGen's lead investigational candidate, PGN-EDO51. The scheduled conference call may provide further insights, potentially driving short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100